• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    OnKure Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/6/25 7:35:09 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OKUR alert in real time by email
    8-K
    false000163771500016377152025-05-062025-05-06

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 06, 2025

     

     

    OnKure Therapeutics, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-40315

    47-2309515

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    6707 Winchester Circle, #400

     

    Boulder, Colorado

     

    80301

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 720 307-2892

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Class A Common Stock, par value $0.0001 per share

     

    OKUR

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 6, 2025, OnKure Therapeutics, Inc. issued a press release reporting financial results for the quarter ended March 31, 2025.

    The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

    All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) of this report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit No.

    Description

    99.1

    Press Release titled "OnKure Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights" dated May 6, 2025.

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    ONKURE THERAPEUTICS, INC.

     

     

     

     

    Date:

    May 6, 2025

    By:

    /s/ Jason Leverone

     

     

     

    Name: Jason Leverone
    Title: Chief Financial Officer

     


    Get the next $OKUR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OKUR

    DatePrice TargetRatingAnalyst
    4/30/2025Outperform
    Evercore ISI
    12/5/2024$33.00Outperform
    Leerink Partners
    10/10/2024$35.00Outperform
    Oppenheimer
    More analyst ratings

    $OKUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by OnKure Therapeutics Inc.

      SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

      11/14/24 4:00:05 PM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by OnKure Therapeutics Inc.

      SC 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)

      11/14/24 10:11:45 AM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by OnKure Therapeutics Inc.

      SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

      10/28/24 4:03:06 PM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OKUR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

      -- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data -- Expansion of the Company's PI3Ka franchise with the planned announcement of a pan-mutant selective development candidate in Q2 2025 -- $96.7M in cash and cash equivalents expected to be sufficient to fund operations through multiple anticipated milestones into Q4 2026 BOULDER, Colo., May 06, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines in oncology, today reported financial results for the quarter ended Mar

      5/6/25 7:30:00 AM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      — PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024 — Expansion of PI3Ka franchise to include a pan-mutant selective program; development candidate expected to be announced in Q2 2025 — $111M in cash and cash equivalents expected to be sufficient to fund operations through multiple PIKture-01 clinical readouts and anticipated milestones into Q4 2026 BOULDER, Colo., March 10, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines in oncology, to

      3/10/25 4:05:16 PM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences

      BOULDER, Colo., March 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that Nicholas Saccomano, Ph.D., President and Chief Executive Officer of OnKure, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Leerink Partners Global Healthcare Conference, in Miami on Tuesday, March 11, 2025, at 4:20 p.m. ET. A live audio webcast will be available through this link and the Investors section of OnKure's website at www.onkure.com. Following the event, a replay will be availa

      3/4/25 8:00:00 AM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OKUR
    SEC Filings

    See more
    • SEC Form 424B3 filed by OnKure Therapeutics Inc.

      424B3 - OnKure Therapeutics, Inc. (0001637715) (Filer)

      5/28/25 4:35:19 PM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OnKure Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - OnKure Therapeutics, Inc. (0001637715) (Filer)

      5/28/25 4:30:14 PM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by OnKure Therapeutics Inc.

      SCHEDULE 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

      5/19/25 3:02:01 PM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OKUR
    Leadership Updates

    Live Leadership Updates

    See more
    • OnKure Announces New Date for Upcoming Investor Call

      BOULDER, Colo., Nov. 25, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that posters selected for presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS), including the poster presenting the preliminary data from the Company's first-in-human PIKture-01 trial of OKI-219, will be published to the symposium's virtual meeting platform for registered attendees on December 10th. OnKure will now hold its investor call to review preliminary data from the PIKture-01 study of OKI-219 on Tuesday, December 10, 2024 at 7:00 a.m. CT (8:00 a.m. E

      11/25/24 5:31:00 PM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OKUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $OKUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $OKUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Mathers Edward T

      4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

      5/30/25 5:05:33 PM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Phillips Andrew John

      4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

      5/30/25 4:54:43 PM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Manke Isaac

      4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

      5/30/25 4:53:31 PM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evercore ISI initiated coverage on OnKure Therapeutics

      Evercore ISI initiated coverage of OnKure Therapeutics with a rating of Outperform

      4/30/25 8:12:14 AM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on OnKure Therapeutics with a new price target

      Leerink Partners initiated coverage of OnKure Therapeutics with a rating of Outperform and set a new price target of $33.00

      12/5/24 8:06:23 AM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on OnKure Therapeutics with a new price target

      Oppenheimer initiated coverage of OnKure Therapeutics with a rating of Outperform and set a new price target of $35.00

      10/10/24 7:48:05 AM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Acorn Bioventures, L.P. bought $2,590,000 worth of shares (1,400,000 units at $1.85) (SEC Form 4)

      4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

      5/19/25 4:43:34 PM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OKUR
    Financials

    Live finance-specific insights

    See more
    • OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219

      -- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated with robust antitumor activity in preclinical models -- Data support the initiation of Part 1b of PIKture-01 evaluating OKI-219 in combination with fulvestrant; first patients dosed, and initial data are expected in 2H-2025 -- Management to host conference call today, December 10, 2024 at 7:00 a.m. CT BOULDER, Colo., Dec. 10, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medi

      12/10/24 7:00:00 AM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium

      OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET BOULDER, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that two abstracts discussing preliminary clinical data and preclinical data for OKI-219, a potential best-in-class, mutant-selective PI3KαH1047R inhibitor, have been selected for presentation during poster sessions at the 2024 San Antonio Breast Cancer Symposium (SABCS), which is being held virtually and in person from D

      11/1/24 5:30:00 PM ET
      $OKUR
      Biotechnology: Pharmaceutical Preparations
      Health Care